We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Chemometec AS | TG:CHY | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.85 | 3.69% | 51.95 | 51.70 | 52.20 | 0.00 | 22:50:06 |
From Jul 2023 to Jul 2024
ANNOUNCEMENT NO. 242
13 September 2023
Guidance for the 2023/24 financial year
ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information.
For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million).
The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2023/24.
Additional information
Rasmus Kofoed, CEO Tel.: (+45) 26 72 68 19
Niels Høy Nielsen, CFO Tel.: (+45) 25 51 87 24
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
1 Year Chemometec AS Chart |
1 Month Chemometec AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
